e-Profile Login and ID Quick Search
FDA Advisory Committee to Discuss Abuse Potential of Dextromethorphan
In response to the increase in dextromethorphan abuse, especially among adolescents, a Food and Drug Administration (FDA) advisory committee will meet to discuss the abuse potential of the drug on September 14, 2010. The committee will also examine the public health benefits and risks of dextromethorphan use as a cough suppressant in prescription and nonprescription drug products. The meeting is prompted by the Drug Enforcement Administration request that the Department of Health and Human Services provide a scientific and medical evaluation and scheduling recommendation for dextromethorphan. Additional details and meeting materials are available in an FDA advisory committee meeting announcement.
